ArticlePharmacology research & perspectives2025
Insights Into Atorvastatin Pharmacokinetics in Rats Reveal Regulation of CYP3A1 by Humanization of SLCO2B1.
Article in Pharmacology research & perspectives, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Crosstalk along the gut-liver axis modulates glutathione and cadmium-induced hepatotoxicity.Frontiers in immunology · 2026Review
- Insights Into Atorvastatin Pharmacokinetics in Rats Reveal Regulation of CYP3A1 by Humanization of SLCO2B1.Pharmacology research & perspectives · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The organic anion transporting polypeptide (OATP) 2B1 is expressed in pharmacokinetically relevant organs such as the liver, the kidney, and the small intestine and it is known to transport a broad range of substrates including statins. In pharmacokinetic studies applying two rat models-one deficient for rat Oatp2b1 and the other expressing the human transporter-we investigated the disposition of atorvastatin, a known OATP2B1 substrate, and observed a reduced exposure and an increased clearance of this OATP2B1 substrate in humanized rats compared to knockout animals. Atorvastatin is predominantly cleared via the bile and due to the clearance increase, we assessed hepatic accumulation of this OATP2B1 substrate. Blood and organs were collected 1 h after administration of the HMG-CoA reductase inhibitor via tail vein injection. Sample analysis revealed lower drug concentrations in serum but also 40% lower hepatic atorvastatin levels in SLCO2B1-humanized rats compared to knockout animals, despite the expected role of OATP2B1 in facilitating hepatocellular uptake. Expression analysis of other drug transporters involved in hepatocellular handling of atorvastatin in treatment-naive rats revealed no differences in the sinusoidal uptake transporter rOatp1b2 and the canalicular efflux transporters rBcrp and rMdr1a between genotypes. However, transcript and protein analysis of rCyp3a1 in liver tissues showed approximately 3-fold higher levels in SLCO2B1-humanized rats compared to rSlco2b1-knockout animals. The increase in rCyp3a1 levels likely reflects an enhanced metabolic rate leading to lower hepatic atorvastatin content. Our finding suggests that humanization of OATP2B1 might influence hepatic disposition of rCyp3a1 substrates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.